| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Experimental Therapeutics |
Seattle Genetics, Inc., Bothell, Washington 98021
The leukocyte activation marker CD30 is highly expressed on the Reed Sternberg cells of Hodgkin’s disease (HD). On normal tissues, CD30 has a restricted expression profile limited to activated T cells, activated B cells, and activated natural killer cells. This expression profile makes CD30 an ideal target for monoclonal antibody (mAb)-based therapies of Hodgkin’s disease. CD30 mAbs have been shown to be effective in in vitro and in vivo models of hematologic malignancies such as anaplastic large cell lymphoma, yet these mAb have not been efficacious in HD models. We have found that a mAb against CD30, AC10, was able to inhibit the growth of HD cell lines in vitro. To generate a more clinically relevant molecule, the variable regions from AC10 were cloned into an expression construct containing the human 
1 heavy chain and 
light chain constant regions. The resulting chimeric antibody, designated SGN-30, retained the binding and in vitro growth-inhibitory activities of the parental antibody. Treatment of HD cell lines with SGN-30 in vitro resulted in growth arrest in the G1 phase of the cell cycle and DNA fragmentation consistent with apoptosis in the HD line L540cy. Severe combined immunodeficient mouse xenograft models of disseminated HD treated with SGN-30 produced significant increases in survival. Similarly, xenograft models of localized HD demonstrated dose-dependent reduction in tumor mass in response to SGN-30 therapy. SGN-30 is being developed for the treatment of patients who have HD that is refractory to initial treatment or who have relapsed and have limited therapeutic options.
This article has been cited by other articles:
|
|
 |
|
  J. H. Mendler and J. W. Friedberg Salvage Therapy in Hodgkin's Lymphoma Oncologist, April 1, 2009; 14(4): 425 - 432. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. M. Kim, C. F. McDonagh, L. Westendorf, L. L. Brown, D. Sussman, T. Feist, R. Lyon, S. C. Alley, N. M. Okeley, X. Zhang, et al. Anti-CD30 diabody-drug conjugates with potent antitumor activity Mol. Cancer Ther., August 1, 2008; 7(8): 2486 - 2497. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. L. Bartlett, A. Younes, M. H. Carabasi, A. Forero, J. D. Rosenblatt, J. P. Leonard, S. H. Bernstein, R. G. Bociek, J. M. Lorenz, B. W. Hart, et al. A phase 1 multidose study of SGN-30 immunotherapy in patients with refractory or recurrent CD30+ hematologic malignancies Blood, February 15, 2008; 111(4): 1848 - 1854. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S.-Y. Nam, Y.-H. Kim, J.-S. Do, Y.-H. Choi, H.-J. Seo, H.-K. Yi, P.-H. Hwang, C.-H. Song, H.-K. Lee, J.-S. Kim, et al. CD30 supports lung inflammation Int. Immunol., February 1, 2008; 20(2): 177 - 184. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Oflazoglu, I. J. Stone, K. A. Gordon, I. S. Grewal, N. van Rooijen, C.-L. Law, and H.-P. Gerber Macrophages contribute to the antitumor activity of the anti-CD30 antibody SGN-30 Blood, December 15, 2007; 110(13): 4370 - 4372. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Zhang, Z. Yao, H. Patel, K. Garmestani, Z. Zhang, V. S. Talanov, P. S. Plascjak, C. K. Goldman, J. E. Janik, M. W. Brechbiel, et al. Effective therapy of murine models of human leukemia and lymphoma with radiolabeled anti-CD30 antibody, HeFi-1 PNAS, May 15, 2007; 104(20): 8444 - 8448. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. V. Krysov, T. F. Rowley, and A. Al-Shamkhani Inhibition of p38 mitogen-activated protein kinase unmasks a CD30-triggered apoptotic pathway in anaplastic large cell lymphoma cells Mol. Cancer Ther., February 1, 2007; 6(2): 703 - 711. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. J. Byrne and J. P. Gockerman Salvage Therapy in Hodgkin's Lymphoma Oncologist, February 1, 2007; 12(2): 156 - 167. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. T. Sandlund Should Adolescents with NHL Be Treated as Old Children or Young Adults? Hematology, January 1, 2007; 2007(1): 297 - 303. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. F. McDonagh, E. Turcott, L. Westendorf, J. B. Webster, S. C. Alley, K. Kim, J. Andreyka, I. Stone, K. J. Hamblett, J. A. Francisco, et al. Engineered antibody-drug conjugates with defined sites and stoichiometries of drug attachment Protein Eng. Des. Sel., July 1, 2006; 19(7): 299 - 307. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. M. Smith, A. Nesterova, S. C. Alley, M. Y. Torgov, and P. J. Carter Potent cytotoxicity of an auristatin-containing antibody-drug conjugate targeting melanoma cells expressing melanotransferrin/p97. Mol. Cancer Ther., June 1, 2006; 5(6): 1474 - 1482. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Iida, H. Misaka, M. Inoue, M. Shibata, R. Nakano, N. Yamane-Ohnuki, M. Wakitani, K. Yano, K. Shitara, and M. Satoh Nonfucosylated Therapeutic IgG1 Antibody Can Evade the Inhibitory Effect of Serum Immunoglobulin G on Antibody-Dependent Cellular Cytotoxicity through its High Binding to Fc{gamma}RIIIa. Clin. Cancer Res., May 1, 2006; 12(9): 2879 - 2887. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. S. K. Sutherland, R. J. Sanderson, K. A. Gordon, J. Andreyka, C. G. Cerveny, C. Yu, T. S. Lewis, D. L. Meyer, R. F. Zabinski, S. O. Doronina, et al. Lysosomal Trafficking and Cysteine Protease Metabolism Confer Target-specific Cytotoxicity by Peptide-linked Anti-CD30-Auristatin Conjugates J. Biol. Chem., April 14, 2006; 281(15): 10540 - 10547. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Boll, H. Hansen, F. Heuck, K. Reiners, P. Borchmann, A. Rothe, A. Engert, and E. Pogge von Strandmann The fully human anti-CD30 antibody 5F11 activates NF-{kappa}B and sensitizes lymphoma cells to bortezomib-induced apoptosis Blood, September 1, 2005; 106(5): 1839 - 1842. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Schnell, M. Dietlein, J. O. Staak, P. Borchmann, K. Schomaecker, T. Fischer, W. Eschner, H. Hansen, F. Morschhauser, H. Schicha, et al. Treatment of Refractory Hodgkin's Lymphoma Patients With an Iodine-131-Labeled Murine Anti-CD30 Monoclonal Antibody J. Clin. Oncol., July 20, 2005; 23(21): 4669 - 4678. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Nagata, T. Ise, M. Onda, K. Nakamura, M. Ho, A. Raubitschek, and I. H. Pastan Cell membrane-specific epitopes on CD30: Potentially superior targets for immunotherapy PNAS, May 31, 2005; 102(22): 7946 - 7951. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. J. Hamblett, P. D. Senter, D. F. Chace, M. M. C. Sun, J. Lenox, C. G. Cerveny, K. M. Kissler, S. X. Bernhardt, A. K. Kopcha, R. F. Zabinski, et al. Effects of Drug Loading on the Antitumor Activity of a Monoclonal Antibody Drug Conjugate Clin. Cancer Res., October 15, 2004; 10(20): 7063 - 7070. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Borchmann, J. F. Treml, H. Hansen, C. Gottstein, R. Schnell, O. Staak, H.-f. Zhang, T. Davis, T. Keler, V. Diehl, et al. The human anti-CD30 antibody 5F11 shows in vitro and in vivo activity against malignant lymphoma Blood, November 15, 2003; 102(10): 3737 - 3742. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Francisco, C. G. Cerveny, D. L. Meyer, B. J. Mixan, K. Klussman, D. F. Chace, S. X. Rejniak, K. A. Gordon, R. DeBlanc, B. E. Toki, et al. cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity Blood, August 15, 2003; 102(4): 1458 - 1465. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
